Compare TG & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | LYEL |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.6M | 195.8M |
| IPO Year | 1994 | 2021 |
| Metric | TG | LYEL |
|---|---|---|
| Price | $5.58 | $14.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $38.38 |
| AVG Volume (30 Days) | ★ 273.7K | 218.6K |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $800,821,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.79 | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $5.26 | $7.20 |
| 52 Week High | $10.53 | $45.00 |
| Indicator | TG | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 28.75 | 62.76 |
| Support Level | N/A | $12.25 |
| Resistance Level | $8.15 | $14.97 |
| Average True Range (ATR) | 0.42 | 1.58 |
| MACD | -0.19 | 0.45 |
| Stochastic Oscillator | 12.52 | 66.05 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.